Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness analyses of laparoscopic versus open surgery

  • Letter
  • Published:
Surgical Endoscopy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chatterjee A, Chen L, Goldenberg EA, Bae HT, Finlayson SR (2010) Opportunity cost in the evaluation of surgical innovations: a case study of laparoscopic versus open colectomy. Surg Endosc 24(5):1075–1079

    Article  PubMed  Google Scholar 

  2. Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696

    Article  PubMed  Google Scholar 

  3. Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406

    Article  PubMed  Google Scholar 

  4. Bali C, Ziogas D, Roukos DH, Baltogiannis G (2010) Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. Ann Surg 251(1):185–186

    Article  Google Scholar 

  5. Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10(4):473–476

    Article  PubMed  Google Scholar 

  6. Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350

    Article  PubMed  Google Scholar 

  7. Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555

    Article  PubMed  CAS  Google Scholar 

  8. Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651

    Article  Google Scholar 

  9. Hottenrott C, Hanisch E, Ziogas D, Roukos DH (2009) Totally laparoscopic gastrectomy: a reality for USA and Europe? Ann Surg Oncol 16(9):2665–2666

    Article  PubMed  Google Scholar 

  10. Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22(5):1402–1404

    Article  PubMed  Google Scholar 

  11. Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250

    Article  PubMed  Google Scholar 

  12. Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392

    Article  PubMed  Google Scholar 

  13. Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798

    Article  PubMed  Google Scholar 

  14. Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6

    Article  PubMed  CAS  Google Scholar 

  15. Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681

    Article  PubMed  Google Scholar 

  16. Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715

    Article  PubMed  Google Scholar 

  17. Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17

    Article  PubMed  Google Scholar 

  18. Roukos DH (2009) Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221

    Article  PubMed  Google Scholar 

  19. Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128

    Article  PubMed  CAS  Google Scholar 

  20. Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995

    Article  PubMed  CAS  Google Scholar 

  21. Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416

    Article  PubMed  Google Scholar 

  22. Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068

    Article  PubMed  Google Scholar 

  23. Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782

    Article  PubMed  Google Scholar 

  24. Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229

    Article  PubMed  Google Scholar 

  25. Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362 author reply 1363

    Article  PubMed  CAS  Google Scholar 

  26. Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian knot”? Ann Surg Oncol 16(3):774–775

    Article  PubMed  Google Scholar 

  27. Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48

    Article  PubMed  CAS  Google Scholar 

  28. Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287

    Article  PubMed  Google Scholar 

  29. Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol. doi:10.1200/JCO.2009.27.7061

  30. Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics. doi:10.2217/PGS.10.104

  31. Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350

    Article  CAS  Google Scholar 

  32. Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361

    Article  PubMed  Google Scholar 

  33. Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Author Christof Hottenrott has no conflicts of interest or financial ties to disclose.

Author information

Authors and Affiliations

  1. Chirurgische Klinik, St. Elisabethenkrankenhaus, Ginnheimer Straße 3, 60487, Frankfurt, Germany

    Christof Hottenrott

Authors
  1. Christof Hottenrott
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hottenrott, C. Cost-effectiveness analyses of laparoscopic versus open surgery. Surg Endosc 25, 990–992 (2011). https://doi.org/10.1007/s00464-010-1271-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00464-010-1271-z

Keywords

Search

Navigation